AIM ImmunoTech (AIM) announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled “Compositions for Treating LONG COVID,” covering compositions of matter of AIM’s proprietary dsRNAs including, for example, Ampligen for use in the treatment of Long COVID.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech Updates Certificate of Incorporation
- AIM ImmunoTech Presents at Maxim Growth Summit 2025
- AIM ImmunoTech presents Phase 1a trial data for faridoxorubicin
- AIM ImmunoTech secures patent in Japan through 2039 for therapy using Ampligen
- AIM ImmunoTech announces publication on effect of Ampligen